Operationally-built medical bidding SaaS with 36,420 verified clinics across 129 countries and $55K Q1 2026 B2B services revenue (incl. $30K Abbott Laboratories). Underfunded, not underbuilt. Capital constraints driving sale. Fully operational, multilingual private medical bidding marketplace, built and bootstrapped over 24 months. Patients post medical cases for free; clinics submit private, competitive bids visible only to the patient. ═══ THE NUMBERS THAT MATTER ═══ → 36,420 verified private clinics & hospitals onboarded across 129 countries → $55,000 in B2B services revenue invoiced in Q1 2026 → $30,000 contract with Abbott Laboratories (NYSE: ABT) — March 2026 → 50 medical specialties covered, 11 languages supported → GDPR / HIPAA / PHIPA / HITECH compliant infrastructure ═══ WHAT THIS ACTUALLY IS ═══ This is infrastructure + a verified supply-side network + proven B2B revenue capability — priced at the cost of replication, with all monetization upside as buyer-captured value. The supply side is complete: 36,420 clinics across 129 countries and 50 specialties, onboarded over 24 months as part of standard two-sided marketplace bootstrapping. The platform's monetization layer (€20/mo subscription + 10% commission) is built, tested, and operational with first paying clinics. It is currently paused alongside marketing. The B2B services channel has independently generated $55,000 in Q1 2026, including a $30,000 contract with Abbott Laboratories (NYSE: ABT) — proving the underlying asset has commercial utility today, before any SaaS reactivation. ═══ WHY I'M SELLING ═══ Direct disclosure: as a solo bootstrapped founder, I lack the marketing capital to activate the asset at the scale it deserves. Marketing was paused. Rather than let the platform sit idle, I'm transferring it to an operator with the resources to unlock its three monetization paths: 1. SaaS subscription activation (convert the 36K free listings into paid tiers) 2. Patient-side acquisition (activate demand in medical tourism hubs) 3. B2B services continuation (the channel that generated $55K in Q1) There are no hidden liabilities. The business is operational, compliant, and current on all obligations. ═══ Q1 2026 B2B REVENUE — VERIFIABLE ═══ → Topclinics ($10,000, January) — clinic chain marketing in Romania → ADI ($15,000, January) — pharma outreach campaign in UAE → Abbott Laboratories ($30,000, March) — pharma outreach in Singapore These are project-based, not recurring. Recurrence potential exists but is buyer-driven and not modeled in the asking price. All invoices and bank statement confirmation available in the data room. ═══ WHAT YOU INHERIT ═══ → Domain → Codebase: complete platform (frontend, backend, admin, integrations) → Database: 36,420 verified clinics across 129 countries, segmented by 50 specialties → Compliance pack: GDPR, HIPAA, PHIPA/PIPEDA, HITECH alignment documentation → Integrations: Stripe, Twilio, Zoom, 11-language translation engine → Compliance-ready architecture (encrypted, anonymized, OTP-protected) → B2B contract relationships from Q1 2026 (warm prospects, not committed accounts) → 30 days founder transition support included ═══ CUSTOMER ACQUISITION ═══ Supply side (clinics): organic outreach + targeted database compilation over 24 months. Free listings during marketplace bootstrapping phase. Zero clinic-side CAC. Demand side (patients): not yet activated. Marketing paused due to capital constraints. Three channels identified for buyer activation: SEO in medical tourism verticals, paid social in cosmetic/dental categories, partnerships with medical tourism agencies. B2B services: outbound enterprise outreach. Q1 2026 generated 3 contracts worth $55K total, including $30K from Abbott Laboratories. ═══ ASKING PRICE: $250,000 ═══ Calibrated to the floor of replication value plus near-term revenue proof: → Database replication cost: ~$150K and 12-18 months to rebuild from scratch → Platform development replacement value: $80K-$150K equivalent agency build → Q1 2026 revenue proof point: $55K invoiced, ~$220K annualized run-rate proxy → Compliance posture: 6+ months to achieve from zero All SaaS activation upside, patient acquisition potential, and B2B scale-up opportunity is included as buyer-captured value above the asking price. ═══ DUE DILIGENCE READY ═══ Full data room available post-NDA, including: → Q1 2026 invoices + anonymized bank statements confirming receipts → Sample export of 200 clinics distributed across top markets (verifiable independently) → Platform demo video + live demo on request → 90-day Buyer Activation Playbook → Compliance documentation → Asset transfer checklist ═══ WHO THIS IS FOR ═══ This is for operators who can extract value from a built asset: → B2B healthcare operators with sales capacity to convert the database → Medical tourism agencies looking for technology infrastructure → Healthcare martech companies seeking distribution → Medtech / pharma marketing agencies with healthcare networks → Private equity / family offices with healthcare portfolio companies I respond to qualified inquiries within 24 hours. Serious buyers will get the full picture — including risks, unknowns, and what I would do differently with capital — in the post-NDA conversation. ═══ ASKING PRICE REASONING ═══ $250,000 is calibrated to verifiable asset value, not speculative ARR projections. Three pillars support this price: 1. REPLICATION COST: Building a verified 36,420-clinic network across 129 countries with current segmentation depth would conservatively require 12-18 months and $150K+ in operational outreach costs. The platform's compliance-ready infrastructure (GDPR, HIPAA, PHIPA, HITECH) represents an additional 6+ months of work. 2. DEVELOPMENT REPLACEMENT VALUE: 24 months of solo development for the bidding engine, multilingual platform (11 languages), Stripe/Twilio/Zoom integrations, OTP authentication, anonymization layer, admin tooling. Comparable agency-built equivalent: $80,000-$150,000. 3. NEAR-TERM REVENUE PROOF: $55,000 invoiced in Q1 2026 from 3 enterprise contracts, including $30,000 from Abbott Laboratories (NYSE: ABT, $200B+ market cap). Annualized run-rate proxy: ~$220K. At 1-2x revenue multiple for an underfunded asset with verified Fortune 500 client relationships, this alone supports $200K-$400K. All activation upside (SaaS subscription tier, patient-side acquisition, B2B services scaling) is included as buyer-captured value above the $250K floor. I am open to serious offers and structured deals (cash + earnout, milestone-based payment). I am not open to offers below $150K — at that price point, the listing returns to "too cheap to be credible" territory that creates buyer suspicion rather than buyer interest.